Full Description
Neuropsychopharmacology and Plasticity: Advances, Mechanisms, and Translational Challenges provides a comprehensive review of how pharmacological treatments intersect with neuroplasticity. Starting with a basic overview, it defines key concepts like synaptic and structural plasticity, explains their molecular foundations, and highlights primary neurotransmitter systems. The book covers both traditional and new psychopharmacological agents, offering historical background and clinical significance. A central theme is the gap between basic science and clinical application, analyzing limitations of animal models and the challenges in applying preclinical plasticity markers to human psychiatric conditions. It critically discusses methodological issues that hinder translating lab findings into effective treatments. The volume reviews methods for measuring plasticity in humans, such as PET imaging, EEG markers, and serum BDNF, noting ongoing issues with sensitivity, specificity, and consistency, especially in psychiatric populations. The effects of rapid-acting antidepressants and psychedelics like ketamine and psilocybin on structural and functional plasticity are examined, along with their potential for long-term neural changes. Chapters also explore combination drug therapies aimed at enhancing plasticity, including HDAC inhibitors and cAMP modulators, emphasizing the need for more systematic testing of these strategies. The role of individual genetic differences, like BDNF polymorphisms and methylation, is analyzed for personalized treatment approaches, raising ethical and practical questions about using genetic and epigenetic profiles. The importance of developmental windows—early life, adolescence, and aging—is discussed concerning age-specific plasticity and treatment effectiveness. The contribution of glial cells to plasticity and their potential as therapeutic targets is also included. Lastly, the volume addresses the methodological, ethical, and regulatory challenges in integrating pharmacotherapy with psychotherapy and offers insights for future clinical trial designs.



